Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAllianz Asset Management GmbH
Latest Disclosed Ownership47,662 shares
Latest Disclosed Value $ 15,769,926
Allianz Asset Management GmbH reports 0.44% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 11, 2026 - Allianz Asset Management GmbH filed a 13F-HR form disclosing ownership of 47,662 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $13,617,033 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 47,875 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -0.44% during the quarter. The current value of the position is $12,415,951 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,662 -213 -0.44 15,770 -17.17 0.0062
2026-02-11 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,875 -58,941 -55.18 19,037 -60.92 0.0193
2025-11-04 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 106,816 -99,177 -48.15 48,708 -27.49 0.0544
2025-07-28 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 205,993 -12,510 -5.73 67,172 13.85 0.0804
2025-05-05 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 218,503 109,632 100.70 59,000 130.31 0.0772
2025-02-03 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 108,871 82,065 306.14 25,618 247.50 0.0342
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,806 8,632 47.50 7,372 66.94 0.0103
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,174 6,660 57.84 4,416 156.74 0.0065
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,514 -2,275 -16.50 1,721 -34.82 0.0027
2024-02-12 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,789 -662 -4.58 2,639 3.13 0.0043
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,451 -2,144 -12.92 2,559 -18.81 0.0043
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,595 -2,052 -11.00 3,152 -15.61 0.0056
2023-05-11 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,647 294 1.60 3,735 -14.35 0.0066
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,353 -3,390 -15.59 4,362 0.23 0.0085
2022-11-08 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,743 -27,968 -56.26 4,351 -39.99 0.0088
2022-08-12 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49,711 4,783 10.65 7,251 -1.17 0.0069
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,928 -6,136 -12.02 7,337 -15.37 0.0055
2022-02-11 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,064 -4,490 -8.08 8,670 -17.34 0.0061
2021-11-10 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,554 20,955 60.57 10,489 78.84 0.0082
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,599 -2,860 -7.64 5,865 10.89 0.0050
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 37,459 7,445 24.81 5,289 35.58 0.0051
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,014 -1,595 -5.05 3,901 -15.23 0.0039
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,609 -7,002 -18.13 4,602 -19.52 0.0054
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,611 -5,214 -11.90 5,718 19.87 0.0066
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,825 -14,881 -25.35 4,770 -29.45 0.0064
2020-02-13 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 58,706 -29,211 -33.23 6,761 -4.60 0.0062
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 87,917 -16,736 -15.99 7,087 -6.66 0.0070
2019-08-08 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 104,653 -19,274 -15.55 7,593 -34.44 0.0071
2019-05-13 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 123,927 -23,886 -16.16 11,581 8.64 0.0115
2019-04-02 2018-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 147,813 -26,637 -15.27 10,660 -30.18 0.0117
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 147,813 -26,637 10,660
2019-04-09 2018-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 174,450 38,720 28.53 15,268 14.21 0.0139
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 174,450 38,720 15,268
2019-04-09 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 135,730 63,975 89.16 13,368 56.42 0.0130
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 135,730 63,975 13,368
2019-04-09 2018-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 71,755 100 0.14 8,546 -6.12 0.0082
2018-05-23 2018-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 71,755 0 8,546 0.0082
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,755 100 8,546
2019-04-17 2017-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 71,655 44,655 165.39 9,103 186.98 0.0072
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,655 44,655 9,103
2019-04-17 2017-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 -3,177 -10.53 3,172 33.00 0.0028
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 -3,177 3,172
2019-04-17 2017-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 30,177 3,177 11.77 2,385 72.33 0.0023
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,177 3,177 2,385
2019-04-17 2017-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 0 0.00 1,384 36.89 0.0014
2017-05-15 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 0 1,384
2019-04-17 2016-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 -63,574 -70.19 1,011 -83.96 0.0009
2017-03-14 2016-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 0 1,011 0.0009
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 1,011
2019-04-17 2016-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 90,574 -2,049 -2.21 6,304 22.67 0.0062
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 90,574 -2,049 6,304
2017-01-24 2016-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 92,623 41,020 79.49 5,139 58.66 0.0055
2016-08-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 92,623 5,139
2016-05-13 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,603 673 1.32 3,239 -32.63 0.0037
2017-01-24 2015-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 50,930 0 0.00 4,808 17.47 0.0054
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,930 4,808
2017-01-24 2015-09-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 50,930 -1,500 -2.86 4,093 -34.88 0.0049
2015-11-20 2015-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 50,930 0 4,093 0.0043
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,930 4,093
2015-09-22 2015-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 52,430 -50,880 -49.25 6,285 -41.74 0.0067
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 52,430 6,285
2017-01-24 2015-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 103,310 23,000 28.64 10,787 38.47 0.0123
2015-05-15 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 103,310 10,787,630
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 80,310 27,860 53.12 7,790 90.14 0.0087
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 52,450 -2,000 -3.67 4,097 19.10 0.0049
2014-08-13 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,450 455 0.84 3,440 -5.10 0.0043
2014-05-28 2014-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 53,995 -22,000 -28.95 3,625 -25.81 0.0044
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 53,995 3,625
2014-02-13 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 75,995 -79,595 -51.16 4,886 -50.94 0.0062
2013-11-14 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 155,590 17,000 12.27 9,959 131.82 0.0132
2013-08-14 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 138,590 138,590 4,296 0.0061
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.